TMED1 Inhibitors
TMED1 inhibitors constitute a group of chemicals that predominantly target the broader cellular processes and pathways that TMED1 is associated with, specifically vesicular protein trafficking. Brefeldin A, for instance, dismantles the Golgi apparatus, directly obstructing protein transport between the ER and the Golgi, potentially suppressing the functions of TMED1. Similarly, Golgicide A, by inhibiting GBF1 ARF-GEF, leads to Golgi disruption, implying indirect effects on proteins like TMED1 involved in trafficking between ER and Golgi.
Monensin, an ionophore, impacts the Golgi function by modulating its internal pH, resulting in alterations to normal protein trafficking. Microtubules, which are essential highways for vesicle movement within cells, can be destabilized by Nocodazole, therefore disrupting processes in which TMED1 participates. A unique approach can be seen with Swainsonine and Tunicamycin. While Swainsonine hampers protein processing in the Golgi by inhibiting mannosidase II, Tunicamycin halts N-linked glycosylation in the ER, which can influence the trajectory and processing of proteins, possibly affecting the roles of TMED1.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
By dismantling the Golgi apparatus, it blocks protein transport between the ER and the Golgi, thus potentially suppressing TMED1's role in vesicular transport. | ||||||
Golgicide A | 1005036-73-6 | sc-215103 sc-215103A | 5 mg 25 mg | $191.00 $683.00 | 11 | |
Targets and inhibits the GBF1 ARF-GEF, leading to Golgi structure disruption, indirectly affecting TMED1's involvement in vesicular trafficking between ER and Golgi. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Alters the internal pH of the Golgi, which can hamper TMED1-associated protein trafficking processes. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Destabilizes microtubules, affecting vesicular transport mechanisms where TMED1 is operational. | ||||||
Exo1 | 461681-88-9 | sc-200752 sc-200752A | 10 mg 50 mg | $84.00 $297.00 | 4 | |
Affects the structure and function of the early secretory pathway, directly influencing TMED1's role in COPI and COPII mediated trafficking. | ||||||
Swainsonine | 72741-87-8 | sc-201362 sc-201362C sc-201362A sc-201362D sc-201362B | 1 mg 2 mg 5 mg 10 mg 25 mg | $138.00 $251.00 $631.00 $815.00 $1832.00 | 6 | |
Impedes protein processing in the Golgi by inhibiting mannosidase II, potentially affecting TMED1's trafficking functions. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Hinders N-linked glycosylation in the ER, leading to misfolded proteins which can impact TMED1's trafficking role. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Can modulate protein trafficking and secretion pathways, indirectly affecting the roles where TMED1 is pivotal. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Affects calcium storage in the ER, leading to disrupted protein processing and trafficking, which can hamper TMED1's operational roles. | ||||||
Latrunculin A, Latrunculia magnifica | 76343-93-6 | sc-202691 sc-202691B | 100 µg 500 µg | $265.00 $815.00 | 36 | |
By destabilizing actin filaments, it can disrupt vesicular transport mechanisms where TMED1 plays a part. | ||||||